Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

International Journal of Obesity

Volumn 23, Issue 3, 1999, Pages 304-311

  Naslund E ^a   Barkeling, B ^b   King, N ^c   Gutniak, M ^d   Blundell, J E ^c   Holst, J J ^e   Rossner S ^b   Hellstrom P M ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Multidisciplinary Pain Center   (Sweden)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Appetite; Food intake; Gastric emptying; Insulin; Universal eating monitor

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PARACETAMOL; PEPTIDE YY;

ADULT; APPETITE; ARTICLE; BODY MASS; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HUNGER; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; STOMACH EMPTYING; VAGUS NERVE;

EID: 0033021677     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800818     Document Type: Article

References (41)

1. 1 Holst JJ. Glucagon-like peptide-1 (GLP-1) - a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107: 1848-1855.
2. 2 Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718.
3. 3 Jin SLC, Han VKM, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagon-like peptide-1 (GLP-1), glucagon and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988; 271: 519-532.
4. 4 Kreymann B, Ghatei MA, Burnett P, Williams S, Kanse S, Diani AR, Bloom SR. Characterization of glucagon-like peptide 1(7-36) amide in the hypothalamus. Brain Res 1989; 502: 325-331.
5. 5 Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide 1 and its receptor in rat brain. Endocrinology 1987; 121: 1076-1082.
6. 6 Kanse SM, Kreymann B, Ghatei MA, Bloom SR. Identification and characterisation of glucagon-like peptide 1(7-36amide) binding sites in the rat brain and lung. FEBS Lett 1988; 241: 209-214.
7. 2 in the central control of feeding behaviour. Digestion 1994; 54: 360-361.
8. 8 Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-R856.
9. 9 Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
10. 10 Bloom SR. Glucagon-like peptide-1 and satiety. Reply to Van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL. Nature 1997; 385: 214.
11. 11 Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
12. 12 Gutzweiler JP, Göke B, Drewe J, Ketterer S, Handschin D, Hildebrand P, Winterhalder R, Conen D, Beglinger C. Glucagon-like peptide-1 is a physiologic regulator of food intake in humans. Gastroenterology 1997; 112: A1153 (Abstr).
13. 13 Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 1996; 38: 916-919.
14. 14 Näslund E, Grybäck P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, Hellström PM. Distal small bowel hormones: correlation to fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43: 945-952.
15. 15 Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide-1 (GLP-1) increases the period of postprandial satiety and slows gastric emptying in obese humans. Am J Clin Nutr 1998; 68: 525-530.
16. 16 Barkeling B, Rössner S, Björvell H. Effects of a high-protein meal (meat) and a high-carbohydrate meal (vegetarian) on satiety measured by automated computerized monitoring on subsequent food intake. Int J Obes 1990; 14: 743-751.
17. 17 Blundell J, Rogers P, Hill A. Evaluating the satiating power of foods: Implications for acceptance and consumption. In: Solms J (ed). Chemical composition and sensory properties of food and their influence on nutrition. Academic Press: London, 1988; 205-219.
18. 18 Gutniak MK, Larsson H, Heibner SJ, Juneskans TO, Holst JJ, Ahren B. Therapeutic levels of glucagon-like peptide-1 can be obtained in humans by a buccal tablet. Diabetes Care 1996; 19: 843-848.
19. 19 Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 invitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
20. 20 Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994; 43: 535-539.
21. 21 Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression. In: Michael Conn P (ed). Methods in neurosciences, vol 5: neuropeptide technology. Academic Press: San Diego, 1991, 3-22.
22. 22 Ekman R, Wahlestedt C, Bottcher G, Sundler F, Håkanson R, Panula P. Peptide YY-like immunoreactivity in the central nervous system of the rat. Regul Peptides 1986; 16: 157-168.
23. 23 Maddern G, Miners J, Collins PJ, Jamieson GG. Liquid gastric emptying assessd by direct and indirect techniques: radio-nuclide labelled liquid emtpying compared with a simple paracetamol marker method. Aust NZ J Surg 1985; 55: 203-206.
24. 24 Ørskov C, Wettergren A, Holst JJ. Secreation of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665-670.
25. 25 Hill SW, McCutcheon NB. Contribution of obesity, gender, hunger, food preference, and body size to bite size, bite speed and rate of eating. Appetite 1984; 5: 73-83.
26. 26 Hylander B, Barkeling B, Rössner S. Eating behaviour in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1992; 6: 592-597.
27. 27 Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC, Bernstein IL, Seeley R. Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats. Am J Physiol 1997; 272: R726-R730.
28. 28 Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic function in man. Dig Dis Sci 1993; 38: 665-673.
29. 29 Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981 -E988.
30. 30 Khan MI, Read NW. The effect of duodenal lipid infusions upon gastric pressure and sensory responses to balloon distension. Gastroenterology 1992; 102: 467-473.
31. 31 Sepple CP, Read NW. Gastrointestinal correlates of the development of hunger in man. Appetite 1989; 13: 183-191.
32. 32 Schwartz GJ, Moran TH. Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Neurosci Biobehav Rev 1996; 20: 47-56.
33. 33 Ørskov C, Poulsen SS, Møller M, Holst JJ. GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1. Diabetes 1996; 45: 832-835.
34. 34 Navarro M, de Fonseca FR, Alvarez E, Chowen SA, Zueco JA, Gomez R, Eng J, Blazquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNA in rat hyopthalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996; 67: 1982-1991.
35. 35 Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
36. 36 Smith GP, Gibbs J. Satiating effects of cholecystokinin. Ann NY Acad Sci 1994; 713: 236-241.
37. 37 Holst JJ, Schwartz TW, Løvgreen NA. Dinurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 1983; 7: 529-538.
38. 38 Larsen J, Jallad N, Damsbo P. One-week continuous infusion of GLP-1 (7-37) improves glycemic control in NIDDM. Diabetes 1996; 45 (Suppl 2): 233A (Abstr).
39. 39 Donahey JCK, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short-but not long-term food intake or body weight in lean and obese rats. Brain Res 1998; 779: 75-83.
40. 40 Davis HR, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Stbertz EJ, Strader CD, Van Heek M. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes Res 1998; 6: 147-156.
41. 41 Scrocchi LA, Brown TS, MacLusky N, Brubaker PL, Anerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene. Nat Med 1996; 2: 1254-1258.